Gentium to Report Third Quarter 2013 Financial Results

Gentium S.p.A. logo

VILLA GUARDIA (COMO), Italy, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the third quarter 2013 on Thursday, October 31, 2013 and will hold a conference call and live webcast at 7:00 a.m. ET / 12:00 p.m. CET.

A press release detailing the results will be published prior to the event. To participate in the call, interested parties may dial +1 718 354 1157 (USA toll) or 1877 249 9037 (USA toll free) or +44 (0) 20 7784 1036 (international toll) to register ten minutes before the call is scheduled to begin and use confirmation code 5226571. To access the live audio webcast or the subsequent archived recording, visit http://www.gentium.com/investors/event-calendar. The replay can be accessed on the Company's website, http://www.gentium.com/investors/event-calendar or at 1 866 932 5017 (USA toll free) or +44 (0)20 3427 0598 (international toll) using Conference ID 5226571.

About Gentium

Gentium S.p.A. (Nasdaq:GENT), located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the EMA both to treat and to prevent veno-occlusive disease ("VOD") and Fast Track Designation by the U.S. FDA to treat VOD. The European Medicines Agency's Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion on the Company's application for orphan medicinal product status for Defibrotide for the prevention of Graft versus Host Disease ("GvHD"). The positive opinion of the COMP has now been forwarded to the European Union ("EU") commission for final approval and publication in the EU community register. In October 2013, the European Commission granted marketing authorization for Defitelio® (defibrotide) for the treatment of severe VOD in adults and children undergoing hematopoietic stem cell transplantation therapy.

For additional info and to sign up for email alerts, please visit www.gentium.com.

Cautionary Note Regarding Forward-Looking Statements

This release contains "forward-looking statements" that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of Gentium's securities. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."

CONTACT: Gentium S.p.A. Salvatore Calabrese, +39 031-5373-260 SVP Finance, CFO/COO scalabrese@gentium.it or The Trout Group Chelsea Wheeler +1 646 378 2941 cwheeler@troutgroup.com

Source:Gentium S.p.A.